An expert explains the importance of genetic testing in metastatic colorectal cancer, as recent FDA approval highlights its ...

Amgen AMGN announced that the FDA has approved its KRAS inhibitor, Lumakras (sotorasib), in combination with its anti-EGFR antibody, Vectibix (panitumumab), for treating KRAS G12C-mutated ...

Amgen's first-to-market KRAS inhibitor Lumakras has so far failed to live up to once-lofty sales expectations, but a new FDA approval could lend momentum to its growth. The US regulator has ...

Dr. Marwan G. Fakih explains that KRAS mutations, found in 45% of patients with colorectal cancer, include the rare KRAS G12C mutation, leading to Lumakras approval.

combination therapy for treating adults with KRAS G12C-mutated metastatic colorectal cancer. "Amgen opens new drug substance facility in North Carolina, US" was originally created and published by ...

With a ribbon cutting at one facility and a groundbreaking for another Friday, Amgen takes another concrete step towards a promise to create hundreds of jobs in Holly Springs. The $1.02 billion ...

Three years after beginning construction in southwestern Wake County, the pharmaceutical company Amgen celebrated the completion of its $550 million manufacturing plant in the town of Holly ...

Sales of the firm's bispecific T-cell engager Blincyto increased more than 50 percent from the fourth quarter of 2023 to 2024.